Q32 Bio Inc. (QTTB)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-59.79	-47.73	-53.74	-42.81	-37.56
Depreciation & Amortization	0.48	0.49	0.5	0.37	0.05
Other Amortization	0.21	0.19	0.09	0.1	0.1
Loss (Gain) From Sale of Assets	-	-	-	0.02	-
Loss (Gain) From Sale of Investments	0.53	0.45	-	-	-
Loss (Gain) on Equity Investments	1.45	1.63	-	-	-
Stock-Based Compensation	5.31	4.39	1.43	1.24	0.75
Other Operating Activities	-2.55	-17.49	6.74	3.18	-
Change in Accounts Payable	-2.25	-1.04	2.03	-1.24	1.1
Change in Unearned Revenue	-	-	-25.85	25.85	-
Change in Other Net Operating Assets	-9.04	-8.59	50.13	2.34	2.58
Operating Cash Flow	-65.65	-67.72	-18.68	-10.96	-32.98
Capital Expenditures	-0.08	-0.08	-0.01	-2.49	-0.16
Sale of Property, Plant & Equipment	-	-	-	0.02	-
Investment in Securities	19.9	20	-	-	-
Investing Cash Flow	19.83	19.93	-0.01	-2.47	-0.16
Long-Term Debt Issued	-	7	5.5	30	-
Long-Term Debt Repaid	-	-	-5.2	-	-
Net Debt Issued (Repaid)	-	7	0.3	30	-
Issuance of Common Stock	1.69	43.69	0.11	0.07	0.12
Other Financing Activities	-5.9	44.44	-	-	-
Financing Cash Flow	-4.21	95.14	0.41	30.07	20.11
Net Cash Flow	-50.03	47.35	-18.28	16.65	-13.03
Free Cash Flow	-65.72	-67.79	-18.68	-13.44	-33.14
Free Cash Flow Margin	-	-	-	-202.10%	-
Free Cash Flow Per Share	-5.42	-7.02	-53.52	-1.91	-5.12
Levered Free Cash Flow	-48.59	-37.95	-41.84	-8.73	-
Unlevered Free Cash Flow	-47.74	-37.27	-40.68	-8.83	-
Change in Net Working Capital	14.36	0.75	12.44	-16.57	-

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q